RPL17 and non-small cell lung carcinoma: Recent advancements in immune checkpoint inhibitors have transformed the treatment of advanced non-small cell lung cancer (NSCLC) using targets known immune checkpoint molecules, such as the programmed death-ligand 1 (PD-L1) and its receptor, the programmed death-1 (PD-1) 1.